Chronic Heart Failure Clinical Trial
Official title:
Influence of Exercise Therapy on Insulin Resistance in Patients With Heart Failure
The purpose of this study is to investigate the effects of a combined training programme on
insulin resistance, exercise tolerance, muscle strength, body composition and cardiac
function in chronic heart failure patients.
It is assumed that the above mentioned clinical parameters will improve due to physical
exercise.
1. Background and study aims During the last decades, the prevalence of (pre)diabetes but
also of chronic heart failure (CHF) has increased dramatically. Somehow, both
conditions are linked, but the mechanisms involved have not been completely clarified
yet. It is clear that the presence of (pre)diabetes in CHF patients affects morbidity
and mortality. Although feasibility, safety and beneficial effects of exercise training
in CHF are generally acknowledged, its effects on insulin resistance are not well
understood. Therefore, the presented study aims to investigate the effect of ET on
insulin resistance and the possible link with cardiac function, exercise tolerance,
muscle strength and body composition in CHF patients.
2. What does the study involve?
A randomized controlled study (n=30) will be performed over a period of 12 weeks.
Following study inclusion, baseline measurements will be performed in 1 week. They
include:
- a maximal exercise test on a bicycle ergometer to assess exercise tolerance,
- two oral glucose tolerance tests to assess fasting and post-exercise insulin
resistance,
- a venous blood sample to determine HbA1c, blood lipids, BNP,
- a muscle strength measurement on a isokinetic dynamometer,
- assessment of body composition via dual energy x-ray absorptiometry,
- cardiac echography,
- questionnaires to assess health-related quality of life,
- a questionnaire (IPAQ) and a pedometer (3 days) to assess physical activity.
Following baseline measurements, subjects will be randomized to a control group
(CON, n=10) and an exercise intervention group (EX, n=20), matching for gender and
reduced/preserved ejection fraction and glucose tolerance. Hereafter, CON will
receive usual care and will be advised to maintain their normal lifestyle, EX
subjects will be enrolled in a 12-week training program. Following 6 (MID) and 12
(POST) weeks of exercise training including progressive training load adaptations,
baseline measurements will be repeated in all patients.
3. What are the possible benefits and risks of participating?
- Benefits: patients receive a free training program with personal and professional
supervision. After completing the study, they receive a report with personal
results and evaluation of training effects.
- Risks: the usual risks of exercise tolerance testing and exercise training in a
CHF population are limited because training sessions are held in the supervised
conditions of the Jessa hospital and because training characteristics are
according to guidelines of the European Society of Cardiology. Exposure to x-rays
during body composition assessment is very low, almost negligible.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03597646 -
The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure
|
N/A | |
Terminated |
NCT04065997 -
Apogee International
|
||
Withdrawn |
NCT03675113 -
Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02916160 -
Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study
|
Phase 4 | |
Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
Completed |
NCT02247245 -
The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.
|
N/A | |
Completed |
NCT02268500 -
VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
|
Phase 4 | |
Terminated |
NCT01906957 -
Cognition and Exercise Training
|
N/A | |
Completed |
NCT01919918 -
Muscle Afferent Feedback Effects in Patients With Heart Failure
|
Phase 1 | |
Not yet recruiting |
NCT01669395 -
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial
|
N/A | |
Completed |
NCT00984529 -
Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
|
N/A | |
Recruiting |
NCT00863421 -
Sleep Disordered Breathing in Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02840565 -
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
|
Phase 1 | |
Completed |
NCT02441218 -
Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study
|
Phase 3 | |
Completed |
NCT00149409 -
Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure
|
Phase 2/Phase 3 | |
Terminated |
NCT05532046 -
A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)
|
Phase 1 | |
Recruiting |
NCT04984928 -
Readmission Risk of Patients With Heart Failure.
|
||
Completed |
NCT02814097 -
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Active, not recruiting |
NCT05560737 -
ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
|
||
Recruiting |
NCT03286127 -
Palliative Outcome Evaluation Muenster I
|